From:

Saad Enouri, BVSc, MSc, PhD
Research Associate, Canadian gFARAD
Ontario Veterinary College
senouri@uoguelph.ca
Telephone: 519-824-4120 ext. 54984

To: [redacted]
Telephone: [redacted]
Fax: [redacted]
Email: [redacted]

Re: Bovatec 20® Medicated Premix, Surmax™ Premix
Case Id: ON-041420-21350
Date of Response: Apr 15, 2020 9:51:25 AM

Case Information:

Date Submitted	Apr 14, 2020 9:32:21 PM
Species	Turkeys
Number of Animals	25000
Location of Animals	Ontario
Reason for Use	Metaphylaxis
Additional Information	anticoccidial and anti necrotic control for growning turkey flock

Drugs Administered

Drug Trade Name	Generics	Route	Dose	Diseases
Bovatec 20® Medicated Premix	• lasalocid sodium	Oral - Feed	100 ppm (in feed) Continuously for 63 days	• **Alimentary:** coccidiosis
Surmax™ Premix	• avilamycin	Oral - Feed	15 ppm (in feed) Continuously for 63 days	• **Alimentary:** necrotic enteritis - clostridium perfringens

Response and Recommendation: *2 days*

Lasalocid is approved for use in turkey feeds for the prevention of coccidiosis at 100 ppm to be fed continuously “from day one (1) for sixteen (16) weeks for males and fourteen (14) weeks for females” with a zero day withdrawal time. Avilamycin is not approved for use in turkeys in Canada, and there are no maximum residue limits for turkeys. Therefore, any amount detected at slaughter will constitute a violative residue. The CgFARAD™ was able to obtain tissue depletion data for

avilamycin used at 45 ppm for 21 days in turkeys from Elanco. Based on the results of the Elanco study, following a 24 hours withdrawal interval should be sufficient for the use of avilamycin up to 45 ppm for 21 days in turkeys. Due to concerns regarding antimicrobial resistance, the Veterinary Drugs Directorate will no longer approve antimicrobials for continuous use throughout the production cycle and they strongly discourage extended durations of therapy. Therefore, we suggest that extended treatments with avilamycin should be avoided whenever possible and if used beyond 21 days, we recommend extending the above recommendation to at least 2 days. We are not aware of any interaction between these drugs that would require further extension of the withdrawal intervals. Therefore, we recommend following a withdrawal interval of at least 2 days for this combination.

Therefore, the Canadian gFARAD recommends a withdrawal interval of 2 days, which should be sufficient so that detectable residues are not found. Furthermore, this recommendation for residue avoidance does not address the risks of developing or transmitting antimicrobial resistance from treated animals to other animals or humans following the extralabel use of this antimicrobial. Because the Canadian gFARAD withdrawal recommendation is not an official withdrawal time and is based on data that has not been reviewed nor approved by the Veterinary Drugs Directorate or the Canadian Food Inspection Agency, responsibility for residue violations rests with the attending veterinarian.

To review this request in CgFARAD:
https://farad.usask.ca/cgfarad/vet/viewRequest?id=21350&langen